United States Health

Scholar Rock (NASDAQ:SRRK) reported third-quarter 2026 revenue of US$570,000 from initial shipments of ISEMBYLD, missing analyst estimates of US$1.43 million despite reporting a smaller-than-expected loss per share.

Hims & Hers Health (NYSE:HIMS) shares fell as much as 15% on Tuesday after the telehealth company issued fourth-quarter revenue guidance below analyst expectations, despite reporting 49% third-quarter revenue growth to US$890.4 million.

PepGen (NASDAQ:PEPG) reported positive clinical results from its Phase 2 FREEDOM2-DM1 trial, demonstrating mean splicing correction of 46.5% in the 10 mg/kg multiple ascending dose cohort evaluating PGN-EDODM1 for myotonic dystrophy type 1 (DM1).

Liquidia (NASDAQ) reported third-quarter 2026 YUTREPIA net product sales of $222.7 million, up 31% from the previous quarter and compared with $51.7 million a year earlier.

Keenova Therapeutics (NYSE:MNK) reported third-quarter 2026 net sales of $549.5 million from continuing operations, up 32% year-over-year, and raised its full-year financial outlook.

MaxCyte (NASDAQ:MXCT) raised its full-year 2026 revenue guidance to at least $34.5 million after reporting third-quarter revenue of $10.2 million, up 49% year-over-year.

Zura Bio (NASDAQ:ZURA) shares plunged approximately 76% after its experimental drug tibulizumab failed to meet the primary endpoint in a Phase 2 trial involving 247 patients with hidradenitis suppurativa.

Abeona Therapeutics (NASDAQ:ABEO) reported third-quarter 2026 net ZEVASKYN revenue of US$13.5 million, an 18% increase from the previous quarter.

Charles River Laboratories International (NYSE:CRL) agreed to acquire Frontage Holdings' bioanalysis and DMPK operations in Exton, Pennsylvania, for approximately US$470 million in cash, plus up to US$75 million in performance-based payments.

Biogen (NASDAQ:BIIB) and UCB reported additional Phase 3 findings associating dapirolizumab pegol with higher treatment response rates than placebo in patients with systemic lupus erythematosus.

argenx (NASDAQ:ARGX) has agreed to acquire the remaining shares of Unnatural Products in a deal worth up to approximately $1.15 billion, expanding its drug discovery capabilities.

Elanco Animal Health Incorporated (NYSE:ELAN) reported third-quarter 2026 revenue of $1.265 billion, representing an 11% increase from the prior-year period, as growth across its Pet Health and Farm Animal businesses supported improved financial performance.